Compare · CHWY vs LOGC
CHWY vs LOGC
Side-by-side comparison of Chewy Inc. (CHWY) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHWY and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
- CHWY is the larger of the two at $8.44B, about 173.1x LOGC ($48.8M).
- Over the past year, CHWY is down 56.7% and LOGC is up 0.0% - LOGC leads by 56.7 points.
- LOGC has been more active in the news (9 items in the past 4 weeks vs 7 for CHWY).
- CHWY has more recent analyst coverage (25 ratings vs 5 for LOGC).
- Company
- Chewy Inc.
- ContextLogic Inc.
- Price
- $20.13-2.42%
- $7.05+1.00%
- Market cap
- $8.44B
- $48.8M
- 1M return
- -14.92%
- +0.00%
- 1Y return
- -56.71%
- +0.00%
- Industry
- Catalog/Specialty Distribution
- Catalog/Specialty Distribution
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 7
- 9
- Recent ratings
- 25
- 5
Chewy Inc.
Chewy, Inc., together with its subsidiaries, engages in the pure play e-commerce business in the United States. The company provides pet food and treats, pet supplies and pet medications, and other pet-health products, as well as pet services for dogs, cats, fish, birds, small pets, horses, and reptiles through its chewy.com retail Website, as well as its mobile applications. It offers approximately 70,000 products from 2,500 partner brands. The company was founded in 2010 and is headquartered in Dania Beach, Florida. Chewy, Inc. is a subsidiary of PetSmart, Inc.
ContextLogic Inc.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest CHWY
- Chief Executive Officer Singh Sumit covered exercise/tax liability with 8,840 shares, decreasing direct ownership by 0.85% to 885,722 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Billings William G. covered exercise/tax liability with 625 shares, decreasing direct ownership by 2% to 38,937 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Deppe Christopher S. covered exercise/tax liability with 182 shares, decreasing direct ownership by 3% to 6,247 units (SEC Form 4) (tax liability)
- General Counsel & Secretary Hu Da-Wai covered exercise/tax liability with 445 shares, decreasing direct ownership by 10% to 4,203 units (SEC Form 4) (for withholding tax)
- SEC Form DEFA14A filed by Chewy Inc.
- SEC Form DEF 14A filed by Chewy Inc.
- Chewy Announces Fiscal First Quarter Financial Results Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by Chewy Inc.
- SEC Form SCHEDULE 13G filed by Chewy Inc.
- Chewy Announces Participation in the J.P. Morgan 2026 Global Technology, Media and Communications Conference
Latest LOGC
- Director Levy Paul S bought $899,618 worth of shares (99,428 units at $9.05) (SEC Form 4)
- Director Levy Paul S bought $232,344 worth of shares (25,693 units at $9.04) (SEC Form 4)
- SEC Form 4 filed by CFO & COO Stewart Scott Matthew
- SEC Form 3 filed by new insider Stewart Scott Matthew
- ContextLogic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- ContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating Officer
- Director Bobbili Raja bought $1,134,825 worth of shares (130,201 units at $8.72) (SEC Form 4)
- ContextLogic Holdings Inc. Publishes Q&A Following First Quarter 2026 Results
- Director Bobbili Raja bought $1,310,960 worth of shares (150,000 units at $8.74) (SEC Form 4)
- SEC Form 10-Q filed by ContextLogic Inc.